Spyre Therapeutics's market cap is currently $1.32B. The company's EPS TTM is $9.21; its P/E ratio is 2.43; Spyre Therapeutics is scheduled to report earnings on February 27, 2025, and the estimated EPS forecast is $-0.99. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 886.00K	$ 2.33M	$ 18.74M	$ 0.00	$ 0.00
Gross Profit	$ -78.00K	$ 365.00K	$ 16.74M	$ -1.62M	$ -901.00K
Operating Income	$ -242.30M	$ -84.78M	$ -65.65M	$ -81.48M	$ -80.33M
EBITDA	$ -127.82M	$ -83.21M	$ -63.66M	$ -79.27M	$ -77.35M
Net Income	$ -338.79M	$ -83.81M	$ -65.80M	$ -80.89M	$ -78.25M
Balance Sheet
Cash & Short-Term Investments	$ 339.28M	$ 55.71M	$ 93.13M	$ 146.27M	$ 71.95M
Total Assets	$ 341.86M	$ 71.14M	$ 109.93M	$ 161.62M	$ 83.18M
Total Debt	$ 84.56M	$ 4.63M	$ 5.06M	$ 5.45M	$ 5.12M
Net Debt	$ -188.89M	$ -30.23M	$ -10.08M	$ -84.65M	$ -14.13M
Total Liabilities	$ 157.84M	$ 20.84M	$ 25.98M	$ 21.79M	$ 23.10M
Stockholders' Equity	$ 184.02M	$ 50.30M	$ 83.94M	$ 139.83M	$ 60.08M
Cash Flow
Free Cash Flow	$ -99.91M	$ -80.18M	$ -54.29M	$ -80.06M	$ -67.18M
Operating Cash Flow	$ -99.91M	$ -80.14M	$ -53.72M	$ -75.78M	$ -65.69M
Investing Cash Flow	$ -108.39M	$ 57.01M	$ -22.62M	$ -7.60M	$ -1.74M
Financing Cash Flow	$ 361.08M	$ 42.68M	$ 1.39M	$ 154.51M	$ 65.72M

Currency in USD

Spyre Therapeutics Earnings and Revenue History

Income Statement >

Spyre Therapeutics Debt to Assets

Balance Sheet >

Spyre Therapeutics Cash Flow

Cash Flow >

Spyre Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing